Feasibility of an early Alzheimer's disease immunosignature diagnostic test

2012/10/18 by Lucas Restrepo, Phillip Stafford, Stephen Albert Johnston · 2 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Advanced biosensing and bioanalysis techniques #Alzheimer's disease research and treatments #Gene expression and cancer classification

paper · doi:10.1016/j.jneuroim.2012.09.014

openalex publication_date 2012/10/18 · crossref created 2012/10/18 · crossref issued 2013/01/01 · crossref published 2013/01/01 · crossref published-print 2013/01/01 · crossref deposited 2025/09/28 · openalex created_date 2025/10/10 · crossref indexed 2026/01/18 · openalex updated_date 2026/07/29

Citations

• Immunosignaturing Can Detect Products from Molecular Markers in Brain Cancer
• Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase
• Physical Characterization of the “Immunosignaturing Effect”
• Autoreactive antibodies raised by self derived de novo peptides can identify unrelated antigens on protein microarrays. Are autoantibodies really autoantibodies?
• Statistical methods for analyzing immunosignatures
• Application of immunosignatures to the assessment of Alzheimer's disease
• GuiTope: an application for mapping random-sequence peptides to protein sequences
• Comparative study of classification algorithms for immunosignaturing data

Cited by

• Diagnosis and early detection of CNS-SLE in MRL/lpr mice using peptide microarrays
• Immunosignature [wikipedia]